Drugs & Therapy Perspectives

PEER-REVIEWED SUMMARY SLIDE

Oritavancin (KIMYRSA™) : Adis Evaluation

Clinical Considerations

- Has better diluent compatibility (0.9% sodium chloride injection and dextrose 5% in sterile water), full dose in a single vial, a shorter infusion time and a lower infusion volume than the original intravenous (IV) formulation
- Similar pharmacokinetic profile to that of the original IV formulation
- Generally well tolerated with no new safety signals

Plain Language Summary

Background and rationale

- Acute bacterial skin and skin structure infections (ABSSSIs) are heterogeneous bacterial infections that can pose a significant burden on healthcare systems.
- In an attempt to optimize patient outcomes and healthcare utilizations, single-dose regimens have been developed as an alternative to multi-dose and multi-day regimens for ABSSSIs.
- Oritavancin is the first single-dose intravenous (IV) antibacterial therapy approved in the USA for the treatment of adult patients with ABSSSIs.
- With its well-established efficacy and safety profiles, a new IV formulation of oritavancin (KIMYRSA™) has been developed, which has a shorter infusion time and a smaller infusion volume than the originally approved IV formulation (ORBACTIV®).

Clinical findings

- The pharmacokinetic and safety profiles of oritavancin were similar between the two IV formulations.

Conclusion

The new IV formulation of oritavancin is a convenient, effective treatment option for patients with ABSSSIs.